Zehra Betül YALÇINER, Muzaffer Savaş TEPE, Belgin KÜÇÜKKAYA, Nedret Taflan SALEPÇİ, Melek KANDEMİR

Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy

Background: Reversible posterior leukoencephalopa-thy syndrome (RPLS) is a clinicoradiologic syndrome characterized by headache, decreased alertness, sei-zures, visual abnormalities, and white matter changes indicative of cerebral edema. Although the pathogen-esis remains poorly understood, several etiological causes have been described. RPLS is a common com-plication of chemotherapeutics because of its toxic ef-fect on the central nervous system. This syndrome is frequently associated with seizures but rarely seen with status epilepticus and periodic lateralized epileptiform discharges (PLEDs).Case Report: We present a case with metastatic lung cancer that developed RPLS after carboplatin and pa-clitaxel therapy. Our case was admitted to the hospital with status epilepticus and her electroencephalography showed PLEDs.Conclusion: It is important to closely monitor blood pressure and electrolyte levels in patients who take chemotherapeutic agents, especially when there is no previous history of hypertension. It should be kept in mind that RPLS is a causative factor of status epilepti-cus and PLEDs

PDF

___

Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, et al. Cisplatin neurotoxicity presenting as reversible poste- rior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998;19:415-7.
Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM. Reversible posterior leukoencephalopathy syn- drome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol 2001;12:1327-9.
Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome com- plicating cytotoxic chemotherapy for hematologic malignan- cies. Am J Hematol 2004;77:72-6.
Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: A case report and re- view of literature. Oncologist 2007;12:1332-5.
Bhatt A, Farooq MU, Bhatt S, Majid A, Kassab MY. Periodic lateralized epielptiform discharges: an initial electrographic pattern in reversible posterior leukoencephalopathy syndrome. Neurol Neurochir Pol 2008;42:55-9.
Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiological findings. Mayo Clin Proc 2010;85:427-32.
Imai H, Okuno N, Ishihara S, Nakano S, Higuchi S, Arai T, et al. Reversible posterior leukoencephalopathy syndrome after carboplatin and paclitaxel regimen for lung cancer. Intern Med 2012;51:911-5.
Vieillot S, Pouessel D, de Champfleur NM, Becht C, Culine S. Reversible posterior leukoencephalopathy syndrome after car- boplatin therapy. Ann Oncol 2007;18:608-9.
Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology 2007;69:894-7.
Skiba V, Etienne M, Miller JA. Development of chronic epilepsy after recurrent episodes of posterior reversible leukoencepha- lopathy syndrome associated with periodic lateralized epilepti- form discharges. Seizure 2011;20:93-5.
Newton HB. Neurological complications of chemotherapy to the central nervous system. Handb Clin Neurol 2012;105:903- 16.
Sharief U, Perry DJ. Delayed reversible posterior encephalopa- thy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer 2009;8:163-5.
Gorman DJ, Kefford R, Stuart-Harris R. Focal encephalopathy after cisplatin therapy. Med J Aust 1989;150:399-401.
Onujiogu N, Lengyel E, Yamada SD. Reversible posterior leu- koencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol 2008;111:537-9.
Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008;29:1036-42.